Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 6Pemetrexed 3Cisplatin 3Carboplatin 3atezolizumab 2Trastuzumab 2Sugammadex 2Paclitaxel 2Neostigmine 2vinflunine 1poly ICLC 1pembrolizumab 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1delta 24-sterol reductase 1daratumumab 1avelumab 1apatorsen 1abemaciclib 1Water 1Thalidomide 1Surveys and Questionnaires 1Saline Solution 1Rocuronium 1Nephroureterectomy 1Nephrectomy 1Neoadjuvant Therapy 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urologic Neoplasms × apatorsen × Clear all
NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡